|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Division of Pharmacology, University of Antwerp, Wilrijk, Belgium (W.M., G.R.Y.D.M., A.G.H., M.M.K.), Laboratory of Cell Biology and Histology, University of Antwerp, Belgium (J.-P.T.); and Department of Pathology, General Hospital Middelheim, Antwerp, Belgium (M.M.K.)
Several lines of evidence suggest that macrophages play a key role in atherosclerotic plaque destabilization and rupture. Therefore, selective removal of macrophages from plaques via pharmacological therapy could represent a promising approach to stabilize "vulnerable," rupture-prone lesions. Yet, how macrophages can be eliminated from plaques without influencing other cell types, including smooth muscle cells (SMCs), is unknown. In the present study, we report that benzyloxycarbonyl-Val-Ala-DL-Asp(O-methyl)-fluoromethylketone (z-VAD-fmk), a caspase inhibitor with broad specificity, induces nonapoptotic cell death of J774A.1 and RAW264.7 macrophages but not of SMCs. Cell death was characterized by bulk degradation of long-lived proteins, processing of microtubule-associated protein light chain 3, and cytoplasmic vacuolization, which are all markers of autophagy. However, necrosis also occurred, and the number of necrotic cells rapidly increased during z-VAD-fmk treatment. Primary mouse peritoneal macrophages were resistant to z-VAD-fmk-mediated cell death, but unlike SMCs, they underwent z-VAD-fmk-mediated necrosis after pretreatment with interferon-
. Further evidence indicated that the expression level of receptor-interacting protein 1 (RIP1) mediates the sensitivity to z-VAD-fmk. Importantly, upon z-VAD-fmk treatment, J774A.1 macrophages overexpressed and secreted several chemokines and cytokines, including tumor necrosis factor (TNF)
. The combination of z-VAD-fmk and TNF
, but not TNF
alone, induced SMCs necrosis via a mechanism that required RIP1 expression. These results suggest that z-VAD-fmk, despite its selective cell death inducing capacity, would be detrimental for the stability of atherosclerotic plaques due to enlargement of the necrotic core, stimulation of inflammatory responses, and indirect induction of SMC death.
Address correspondence to: Dr. Wim Martinet, Division of Pharmacology, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium. E-mail: wim.martinet{at}ua.ac.be
This article has been cited by other articles:
![]() |
W. Martinet and G. R.Y. De Meyer Autophagy in Atherosclerosis: A Cell Survival and Death Phenomenon With Therapeutic Potential Circ. Res., February 13, 2009; 104(3): 304 - 317. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Mack, A. Sickmann, D. Lembo, and W. Brune Inhibition of proinflammatory and innate immune signaling pathways by a cytomegalovirus RIP1-interacting protein PNAS, February 26, 2008; 105(8): 3094 - 3099. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J.L. Van De Parre, W. Martinet, S. Verheye, M. M. Kockx, G. Van Langenhove, A. G. Herman, and G. R.Y. De Meyer Mitochondrial uncoupling protein 2 mediates temperature heterogeneity in atherosclerotic plaques Cardiovasc Res, January 15, 2008; 77(2): 425 - 431. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Croons, W. Martinet, A. G. Herman, J.-P. Timmermans, and G. R. Y. De Meyer Selective Clearance of Macrophages in Atherosclerotic Plaques by the Protein Synthesis Inhibitor Cycloheximide J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 986 - 993. [Abstract] [Full Text] [PDF] |
||||